Gastrointestinal bleeding

BioElectronics Corporation Announces the Publication of a Canine Arthritis Study

Retrieved on: 
Monday, March 25, 2024
Prevalence, Exercise, Gastrointestinal bleeding, Risk, GI, Sale, Nonsteroidal anti-inflammatory drug, Running, Veterinary medicine, Motion, OA, Chronic pain, Quality of life, Osteoarthritis, Arthritis, Dog, PROM, Aspirin, Cartilage, Bioelectronics, FDA, Animal, BIEL, Ibuprofen, Audit

Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N=26) were reduced from 4.26 to 2.31 (45%) compared to no improvement in the placebo group (N=23) over the study period. Average PROM scores increased by 5.51 (4.59--6.23) degrees relative to the placebo group. Ninety-six percent of the treatment group showed either increased PROM or improved behavioral changes or both compared to 4% for the placebo group. Most changes occurred within the first 8 days of treatment.

Key Points: 
  • The study was published online by Veterinary Medicine & Science, and can be viewed here: https://doi.org/10.1002/vms3.1408
    A randomized, blinded, placebo-controlled 14-day study of 60 dogs having prior veterinary-diagnosis OA in at least one limb joint.
  • BioElectronics’ Model 088 device was secured near the cervical region of the dog’s spine.
  • Osteoarthritis is the most common type of arthritis in dogs and is the most common source of chronic pain in older dogs.
  • Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device into the veterinary medicine market.

Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India

Retrieved on: 
Friday, March 22, 2024
Cardiac output, U.S. FDA, Internal bleeding, Partnership, System, Patient, Research, Trauma, Diarrhea, Hypovolemic shock, Mortality, Gastrointestinal bleeding, Manuscript, Laboratory, Blood volume, Standard of care, DRUGS, Clinical trial, Resuscitation, Safety, DCGI, Phase, Vomiting, Blood, FDA, Food, Shock (mechanics), Emerging market, Generic drug

Developed by Pharmazz for potential global use, Centhaquine is a resuscitative agent presently indicated for treating hypovolemic shock by Drugs Controller General of India (DCGI).

Key Points: 
  • Developed by Pharmazz for potential global use, Centhaquine is a resuscitative agent presently indicated for treating hypovolemic shock by Drugs Controller General of India (DCGI).
  • As per the agreement, Dr. Reddy's has received exclusive rights to market and distribute Centhaquine in India.
  • For patients with hypovolemic shock, I believe Dr. Reddy's is the best partner for Pharmazz to market Centhaquine, an innovative, first-in-class novel resuscitative agent, in India."
  • U.S. FDA clearance of our Phase III IND is an important milestone for Pharmazz and the potential future treatment of hypovolemic shock patients.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Retrieved on: 
Wednesday, January 24, 2024
System, Death, Allergy, Heron, Patient, Vitamin, Naproxen, Elective surgery, SAN, Health, Partnership, Foot, Gastrointestinal bleeding, Ibuprofen, Vomiting, Anemia, Ankle, Stroke, Heart failure, Medicine, Nonsteroidal anti-inflammatory drug, Patient satisfaction, Cartilage, Risk, Meloxicam, Pain, VAN, Cross-link, Food, Constipation, Pregnancy, NDA, Anesthetic, Aspirin, Tears, FDA, Ulcer, Liver, Boxed warning, New Drug Application, Headache, Bupivacaine, Human, Blood, Pharmaceutical industry

SAN DIEGO, Jan. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved its supplemental New Drug Application ("NDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. ZYNRELEF was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.

Key Points: 
  • ZYNRELEF was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.
  • This expanded indication for ZYNRELEF will now cover an estimated 13 million procedures annually, an estimated increase of 86% over prior indicated procedures.
  • To obtain this labeling expansion, Heron successfully conducted studies for cesarean section, spinal surgery, augmentation mammoplasty, and total shoulder arthroplasty.
  • The most common side effects of ZYNRELEF are soft tissue procedures: vomiting and orthopedic procedures: constipation and headache.

AnX Robotica Announces FDA Clearance for ProScan™: A Groundbreaking AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy

Retrieved on: 
Wednesday, January 3, 2024
Endoscopy, Gastrointestinal bleeding, Multimedia, Physician, Marketing, FDA, ProScan, Digestive, Health, Agostino Gemelli University Policlinic, Patient, Robotics, Medical device

Through the rigorous De Novo Submission Process, the FDA has granted clearance for ProScan, making it the first AI Assisted Reading Tool designed to aid small bowel capsule endoscopy reviewers for adult patients in whom the capsule endoscopy images were obtained for suspected small bowel bleeding.

Key Points: 
  • Through the rigorous De Novo Submission Process, the FDA has granted clearance for ProScan, making it the first AI Assisted Reading Tool designed to aid small bowel capsule endoscopy reviewers for adult patients in whom the capsule endoscopy images were obtained for suspected small bowel bleeding.
  • First AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy.
  • ProScan software, an artificial intelligent (AI) assisted reading tool, leverages cutting-edge technology to revolutionize the field of gastroenterology.
  • "We are delighted to announce the FDA clearance of NaviCam ProScan, a transformative AI Assisted Reading Tool that addresses a critical need in the realm of small bowel capsule endoscopy," said Stu Wildhorn, Vice President of Marketing and Product Management at AnX Robotica.

Healthgrades Awards Southern California MemorialCare Hospitals with More than 40 Specialty Awards, with Nine National Nods

Retrieved on: 
Tuesday, October 24, 2023
GI, Stroke, Respiratory failure, Medicare, Physician, Mortality, Bowel obstruction, Data science, Doctor of Philosophy, Statistics, Research, Hospital, Da Vinci Surgical System, Sepsis, Nursing, Patient, Chronic obstructive pulmonary disease, Long Beach Medical Center, Heart failure, Gastrointestinal bleeding, Nursing care plan, Pharmaceutical industry, Healthgrades

Orange Coast Medical Center was named in the Top 10% of the nation for coronary interventional procedures and critical care receiving excellence awards.

Key Points: 
  • Orange Coast Medical Center was named in the Top 10% of the nation for coronary interventional procedures and critical care receiving excellence awards.
  • These achievements place MemorialCare's hospitals in the upper echelon of hospitals nationally for specialty care and reflect the organization's commitment to consistently delivering the best care possible.
  • By focusing on what matters most, patient outcomes, Healthgrades ratings provide critical feedback for both patients and hospitals.
  • And, by shining a light on strengths and weaknesses, Healthgrades ratings help direct hospitals to opportunities for clinical improvement.

Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia

Retrieved on: 
Thursday, August 10, 2023
Health, Genetics, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Hypersensitivity, Cholinesterase, Nausea, Bethanechol, Bradycardia, Peptic ulcer disease, Asthma, Neuromuscular blocking agents, Cholinergic, Partnership, Alzheimer's disease, Diarrhea, Gastrointestinal tract, IQVIA, Roflumilast, Skin, History, Orthostatic syncope, CNS, Heart block, Dementia, Tablet, Anesthesia, Vomiting, Enzyme inhibitor, Incidence, Patient, Chloride, Gastrointestinal bleeding, Nonsteroidal anti-inflammatory drug, FDA, Relaxation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cholinesterase inhibitor, Safety, Food, Caregiver, Pharmaceutical industry, Residential care, Dietary supplement, Corium, Donepezil, Lotus

Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical (1795:TT; “Lotus”), a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.

Key Points: 
  • Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical (1795:TT; “Lotus”), a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.
  • The companies expect to file for regulatory approval in some Asian markets later this year.
  • Under the terms of the agreement, Lotus will have exclusive rights to commercialize ADLARITY® in the applicable territory and will be responsible for the regulatory approval process.
  • According to IQVIA data, the market size of donepezil in the 10 markets in the territory is USD 185 Million.

Motus GI Announces Purchase Agreement for the Pure-Vu System® from Banner Desert Medical Center

Retrieved on: 
Thursday, July 20, 2023
Endoscopy, Bleeding, CRC, Gastrointestinal tract, Banner Desert Medical Center, Research, EVS, Colon, Hematochezia, Colonoscopy, Hospital, Patient, Risk, Colorectal cancer, Blood, Gastrointestinal bleeding, Diagnosis, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, EU, GI

Banner Desert Medical Center is a state-of-the-art 615-bed short-term acute care hospital located in Mesa, Arizona.

Key Points: 
  • Banner Desert Medical Center is a state-of-the-art 615-bed short-term acute care hospital located in Mesa, Arizona.
  • Dr. Mankanwal Sachdev, Director of Endoscopy at Banner Desert Medical Center stated, “The Banner Desert Medical Center prides itself for adopting new technologies that allow us to provide the best care possible to our patients.
  • We believe the Pure-Vu System will provide us unique capabilities that support completing procedures for patients with incomplete bowel preparation.
  • Also, as a level I trauma center, we are excited about the future expansion of the platform to help address Upper GI bleeding which can be a life threating clinical concern.”
    “We are excited to engage the GI team at Banner Desert Medical Center as they implement the Pure-Vu System.

Global Smart Pills Technology Market Report 2023: Sector is Expected to Reach $7,500 Billion by 2030 at a CAGR of 8.8% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 11, 2023
Biotechnology, Technology, IOT (Internet of Things), Diabetes, Health, Oncology, Health Technology, Medical Devices, Infectious Diseases, Artificial Intelligence, Hardware, Systems Failure, Communication, Crohn's disease, Prevalence, Hospice, Capsule endoscopy, Cancer, MEA, Tisbury Great Pond Target Area, Endoscopy, USD, SPES, Tablet, Incidence, Nursing, Esophageal motility disorder, Stomach, Miniaturization, Application, Gastrointestinal bleeding, Plant growth analysis, Conditional sentence, Diagnosis, Growth, Hospital, APT, Transport, Coeliac disease, MNA, Medical device, Birth control, Esophagus, Disease, Region

The global Smart Pills Technology market is a growing segment in the transportation industry.

Key Points: 
  • The global Smart Pills Technology market is a growing segment in the transportation industry.
  • The global smart pills technology market is expected to grow significantly over the forecast period due to increasing demand for non-invasive diagnostic tools and personalized medicine.
  • Additionally, advancements in wireless communication technologies and the miniaturization of electronic components are also driving the growth of the smart pills technology market.
  • Smart Pills Technology Market is segmented based on the Application, target area, disease, end user, and region.